Thyroid cancer is not one treatment pathway. Papillary and follicular differentiated thyroid cancers can retain iodine uptake and may enter a surgery-plus-radioiodine pathway in selected risk groups, while medullary and anaplastic thyroid carcinomas require different staging, molecular and systemic-treatment decisions. German university centers publish interdisciplinary thyroid-tumor pathways spanning endocrine surgery, nuclear medicine, pathology, endocrinology, oncology and radiation medicine. International patients should send the complete pathology, operative record and imaging before asking whether radioiodine or another treatment is appropriate.
Confirm the histologic subtype before choosing treatment
Heidelberg and Freiburg distinguish differentiated papillary or follicular thyroid cancer from medullary and anaplastic carcinoma because the biology and treatment options differ substantially. The pathology subtype, stage and risk features should be clear before a German team recommends surgery, radioiodine, radiation or systemic treatment.
Surgery is central in many localized thyroid cancers
Heidelberg's endocrine-surgery program treats thyroid tumors within an interdisciplinary thyroid center. The extent of thyroid surgery and lymph-node surgery depends on tumor subtype, size, local invasion, nodal disease, prior operations and the intended postoperative pathway. A second operation after incomplete initial surgery can be more complex and should be reviewed from the original operative and pathology reports.
Radioiodine applies only to appropriate iodine-avid differentiated disease
Heidelberg states that radioiodine can be used for follicular and papillary thyroid cancer because these cells can retain iodine-related function, whereas anaplastic thyroid cancer does not follow the same pathway. Freiburg and Essen publish inpatient I-131 treatment for differentiated thyroid carcinoma after surgery and in selected recurrent or metastatic iodine-avid disease.
Medullary thyroid cancer needs a different work-up
Freiburg publishes a separate clinical pathway for medullary thyroid carcinoma and notes the role of genetic assessment when this subtype is suspected. International records should include calcitonin or other relevant tumor-marker results, pathology and genetic findings when already performed rather than assuming a differentiated-thyroid-cancer pathway applies.
Anaplastic thyroid cancer requires urgent multidisciplinary review
Freiburg maintains a separate anaplastic-thyroid-carcinoma pathway involving surgery, radiation/systemic oncology and molecular tumor-board review according to disease extent and molecular findings. This aggressive subtype should not be delayed while arranging a routine medical-tourism package; the German center should first determine whether transfer is clinically realistic and time-safe.
Molecular findings can matter in advanced or refractory disease
For advanced disease that is not controlled by standard local or radioiodine pathways, current specialist evaluation can include molecular testing and tumor-board review. Because approvals, evidence and trial availability change, patients should send any existing sequencing reports and obtain a current recommendation rather than rely on a static drug list.
Records to send before travelling
The center should be able to reconstruct the diagnosis, operation, stage and iodine-related treatment history before proposing the next step.
- Full thyroid pathology report and subtype
- Original operative report and lymph-node pathology
- Neck ultrasound and current CT/MRI/PET or nuclear-medicine imaging when available
- Thyroglobulin and thyroglobulin-antibody results for differentiated disease when available
- Calcitonin / CEA and genetic results when medullary carcinoma is suspected or confirmed
- Prior radioiodine activities, dates and post-therapy imaging
- Current thyroid-hormone treatment and recent TSH / thyroid laboratory values
- Previous radiation or systemic therapy
- Molecular testing in advanced or refractory disease when available
- A clear question about re-operation, radioiodine, recurrence, metastases or second opinion
Follow-up is part of the treatment pathway
Freiburg documents long-term thyroid-cancer follow-up through its thyroid clinic, while Essen describes structured post-radioiodine surveillance. Before returning home, clarify the target thyroid-hormone plan, tumor-marker schedule, ultrasound or imaging timetable and which follow-up can be transferred to the home-country endocrinology or oncology team.
Sources and review
This guide was last source-reviewed on 2026-08-30.
- Thyroid cancer – diagnosis and treatment — Heidelberg University Hospital ↗
- Endocrine Surgery and interdisciplinary thyroid center — Heidelberg University Hospital ↗
- Thyroid carcinoma / endocrine tumor center and clinical pathways — University Medical Center Freiburg ↗
- Thyroid cancer clinic and radioiodine pathway — University Medical Center Freiburg ↗
- Radioiodine therapy for thyroid carcinoma — University Hospital Essen ↗